Interventional treatment combined with immunotargeted therapy in unresectable combined hepatocellular-cholangiocarcinoma: a real-world retrospective cohort study
The triple combination of interventional treatment, PD-(L)1 inhibitor, and targeted therapy is an effective and safe approach for unresectable cHCC-CCA patients.
Authors
- Yansong Lin (ORCID: https://orcid.org/0000-0001-6095-4728)
- Yanqin Wu (ORCID: https://orcid.org/0000-0001-8356-9689)
- Xia Yang (ORCID: https://orcid.org/0009-0000-9682-1193)
- Liyan Wu (ORCID: https://orcid.org/0000-0002-4622-3125)
- Zhen Ding (ORCID: https://orcid.org/0000-0002-5002-5690)
- Fangyi Liu (ORCID: https://orcid.org/0000-0002-8675-0798)
- Lihui Lin (ORCID: https://orcid.org/0009-0003-6041-9452)
- Jing‐Ping Yun
- Yu-Jing Liang
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1591127
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China